Lifeward Business Summary

Lifeward Ltd. (LFWD), formerly ReWalk Robotics, operates as a global medical technology leader specializing in the design and commercialization of life-altering rehabilitation and recovery solutions. The company generates revenue primarily through the direct sale and third-party distribution of its core product portfolio, which includes the ReWalk Personal Exoskeleton, the AlterG Anti-Gravity System, the ReStore soft exo-suit for stroke recovery, and the MyoCycle FES system. Business segments are concentrated in the physical rehabilitation and mobility sectors, with a growing emphasis on securing Medicare and private insurance reimbursement to drive adoption. Within the competitive landscape, Lifeward competes directly with Ekso Bionics, IceCure Medical, and TELA Bio; it maintains a dominant position in the gait-restoration robotic market while currently executing a strategic pivot toward broader biomedical innovation following a transformative 2026 partnership with Oramed Pharmaceuticals. The company’s leadership is anchored by CEO Mark Grant, who joined in June 2025 after a 20-year tenure at Medtronic, where he served as Vice President of the $1.5B Americas Diabetes business. The executive team includes CFO Almog Adar, an internal veteran with deep financial leadership experience, and Vice President of R&D David Hexner, who has spearheaded the technical development of the ReWalk and ReStore platforms since 2011. Effective January 1, 2026, Bob Marshall—current CFO of Lantheus Holdings and a 16-year veteran of Zimmer Biomet—assumed the role of Chairman of the Board, bringing significant radiopharmaceutical and orthopedic expertise to the firm. Founded by Dr. Amit Goffer, the company is backed by notable strategic investor Oramed Pharmaceuticals, which entered a major partnership and investment agreement in early 2026 to stabilize Lifeward’s capital structure and fuel its long-term growth initiatives.